<DOC>
	<DOC>NCT01572727</DOC>
	<brief_summary>This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.</brief_summary>
	<brief_title>A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation</brief_title>
	<detailed_description>Based on the efficacy results at the time of the interim analyses, the DMC recommended stopping the study at Phase II during the interim as it met the protocol pre-specified futility criteria. Consequently, the Phase III portion of the study was not conducted.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Breast cancer that is locally advanced or metastatic HER2 negative disease, and a known hormone receptor status ER/PgR (common breast cancer classification tests) A tumor sample must be shipped to a central lab for identification of biomarkers (PI3K activation status) before randomization Adequate bone marrow and organ function Measurable or nonmeasurable disease Prior chemotherapy for locally advanced or metastatic disease Previous treatment with PI3K or AKT inhibitors Patient has symptomatic CNS metastases Concurrent malignancy or malignancy within 3 years of study enrollment Hematopoietic colonystimulating growth factors or radiation within 24 weeks prior to starting study drug Increasing or chronic treatment (&gt; 5 days) with corticosteroids or another immunosuppressive agent Active heart (cardiac) disease as defined in the protocol Known hypersensitivity or contraindications to use paclitaxel Pregnant or nursing (lactating) woman Certain scores on an anxiety and depression mood questionaire given at screening Other protocol defined criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BKM120</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>PI3K</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>PTEN</keyword>
</DOC>